by The global Cancer vaccine market size was estimated to be around US$ 9.12 billion in 2022. It is projected to reach US$ 26.89 billion by 2032, indicating a CAGR of 11.42% from 2023 to 2032.
Key Takeaways:
- North America dominated the market with the highest market share of 37% in 2022.
- By Type, the preventive segment dominated the market with revenue share of 54% in 2022.
- By Indication, the cervical cancer segment accounted largest revenue share of around 30% in 2022.
- By Technology, the recombinant vaccine segment has held revenue share of 56.8% in 2022.
- By Distribution channel, the hospital segment held the largest share of the market
The market research report on the Cancer vaccine market provides a comprehensive analysis of various key aspects. It includes the definition, classification, and application of Cancer vaccine products. The report examines the development trends, competitive landscape, and industrial chain structure within the industry. Furthermore, it presents an overview of the industry, analyzes national policies and planning, and offers insights into the latest market dynamics and opportunities at a global level.
Get a Sample: https://www.precedenceresearch.com/sample/3241
Report Scope of the Cancer Vaccine Market:
| Report Coverage | Details |
| Market Size in 2023 | USD 10.16 Billion |
| Market Size by 2032 | USD 26.89 Billion |
| Growth Rate from 2023 to 2032 | CAGR of 11.42% |
| Largest Market | North America |
| Fastest Growing Market | Asia Pacific |
| Base Year | 2022 |
| Forecast Period | 2023 To 2032 |
| Segments Covered | By Type, By Indication, and By Distribution Channel |
| Regions Covered | North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa |
Read More: DNA Diagnostics Market Size to Garner USD 20.1 Billion by 2032
The report presents the volume and value-based market size for the base year 2022 and forecasts the market’s growth between 2023 and 2032. It estimates market numbers based on product form and application, providing size and forecast for each application segment in both global and regional markets.
Focusing on the global Cancer vaccine market, the report highlights its status, future forecasts, growth opportunities, key market players, and key market regions such as the United States, Europe, and China. The study aims to present the development of the Cancer vaccine market by considering factors like Year-on-Year (Y-o-Y) growth, in addition to Compound Annual Growth Rate (CAGR). This approach enables a better understanding of market certainty and the identification of lucrative opportunities.
Regarding production, the report investigates the capacity, production, value, ex-factory price, growth rate, and market share of major manufacturers, regions, and product types. On the consumption side, the report focuses on the regional consumption of Cancer vaccine products across different countries and applications.
Buyers of the report gain access to verified market figures, including global market size in terms of revenue and volume. The report provides reliable estimations and calculations for global revenue and volume by product type from 2023 to 2032. It also includes accurate figures for production capacity and production by region during the same period.
The research includes product parameters, production processes, cost structures, and data classified by region, technology, and application. Furthermore, it conducts SWOT analysis and investment feasibility studies for new projects.
This in-depth research report offers valuable insights into the Cancer vaccine market. It employs an objective and fair approach to analyze industry trends, supporting customer competition analysis, development planning, and investment decision-making. The project received support and assistance from technicians and marketing personnel across various links in the industry chain.
The competitive landscape section of the report provides detailed information on Cancer vaccine market competitors. It includes company overviews, financials, revenue generation, market potential, research and development investments, new market initiatives, global presence, production sites, production capacities, strengths and weaknesses, product launches, product range, and application dominance. However, the data points provided only focus on the companies’ activities related to the Cancer vaccine market.
Prominent players in the market are expected to face tough competition from new entrants. Key players are targeting acquisitions of startup companies to maintain their dominance. The report
Reasons to Purchase this Report:
- Comprehensive market segmentation analysis incorporating qualitative and quantitative research, considering the impact of economic and policy factors.
- In-depth regional and country-level analysis, examining the demand and supply dynamics that influence market growth.
- Market size in USD million and volume in million units provided for each segment and sub-segment.
- Detailed competitive landscape, including market share of major players, recent projects, and strategies implemented over the past five years.
- Comprehensive company profiles encompassing product offerings, key financial information, recent developments, SWOT analysis, and employed strategies by major market players.
Major Market Players
- Generex Biotechnology Corporation
- Advaxis Inc.
- Immunocellular Therapeutics, Ltd
- Vaccinogen, Inc.
- GlaxoSmithKline plc (GSK)
- Merck & Co., Inc.
- Dynavax Technologies Corporation
- SANPOWER GROUP CO. LTD. (DENDEREON CORPORATION)
- Amgen Inc.
- UbiVac
Segments Covered in the Report:
By Type
- Preventive Cancer Vaccines
- Therapeutic Cancer Vaccines
- Others
By Indication
- Cervical Cancer
- Prostate Cancer
- Other Indications
By Technology
- Recombinant Cancer Vaccines
- Viral Vector and DNA Cancer Vaccines
- Whole-cell Cancer Vaccines
- Others
By Distribution Channel
- Hospitals
- Government Suppliers
By Geography
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East and Africa
TABLE OF CONTENT
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Cancer Vaccine Market
5.1. COVID-19 Landscape: Cancer Vaccine Industry Impact
5.2. COVID 19 – Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Cancer Vaccine Market, By Type
8.1. Cancer Vaccine Market Revenue and Volume, by Type, 2023-2032
8.1.1 Preventive Cancer Vaccines
8.1.1.1. Market Revenue and Volume Forecast (2020-2032)
8.1.2. Therapeutic Cancer Vaccines
8.1.2.1. Market Revenue and Volume Forecast (2020-2032)
Chapter 9. Global Cancer Vaccine Market, By Indication
9.1. Cancer Vaccine Market Revenue and Volume, by Indication, 2023-2032
9.1.1. Cervical Cancer
9.1.1.1. Market Revenue and Volume Forecast (2020-2032)
9.1.2. Prostate Cancer
9.1.2.1. Market Revenue and Volume Forecast (2020-2032)
9.1.3. Other Indications
9.1.3.1. Market Revenue and Volume Forecast (2020-2032)
Chapter 10. Global Cancer Vaccine Market, By Distribution Channel
10.1. Cancer Vaccine Market Revenue and Volume, by Distribution Channel, 2023-2032
10.1.1. Hospitals
10.1.1.1. Market Revenue and Volume Forecast (2020-2032)
10.1.2. Government Suppliers
10.1.2.1. Market Revenue and Volume Forecast (2020-2032)
Chapter 11. Global Cancer Vaccine Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue and Volume Forecast, by Type (2020-2032)
11.1.2. Market Revenue and Volume Forecast, by Indication (2020-2032)
11.1.3. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
11.1.4. U.S.
11.1.4.1. Market Revenue and Volume Forecast, by Type (2020-2032)
11.1.4.2. Market Revenue and Volume Forecast, by Indication (2020-2032)
11.1.4.3. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Volume Forecast, by Type (2020-2032)
11.1.5.2. Market Revenue and Volume Forecast, by Indication (2020-2032)
11.1.5.3. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
11.2. Europe
11.2.1. Market Revenue and Volume Forecast, by Type (2020-2032)
11.2.2. Market Revenue and Volume Forecast, by Indication (2020-2032)
11.2.3. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
11.2.4. UK
11.2.4.1. Market Revenue and Volume Forecast, by Type (2020-2032)
11.2.4.2. Market Revenue and Volume Forecast, by Indication (2020-2032)
11.2.4.3. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
11.2.5. Germany
11.2.5.1. Market Revenue and Volume Forecast, by Type (2020-2032)
11.2.5.2. Market Revenue and Volume Forecast, by Indication (2020-2032)
11.2.5.3. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
11.2.6. France
11.2.6.1. Market Revenue and Volume Forecast, by Type (2020-2032)
11.2.6.2. Market Revenue and Volume Forecast, by Indication (2020-2032)
11.2.6.3. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Volume Forecast, by Type (2020-2032)
11.2.7.2. Market Revenue and Volume Forecast, by Indication (2020-2032)
11.2.7.3. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
11.3. APAC
11.3.1. Market Revenue and Volume Forecast, by Type (2020-2032)
11.3.2. Market Revenue and Volume Forecast, by Indication (2020-2032)
11.3.3. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
11.3.4. India
11.3.4.1. Market Revenue and Volume Forecast, by Type (2020-2032)
11.3.4.2. Market Revenue and Volume Forecast, by Indication (2020-2032)
11.3.4.3. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
11.3.5. China
11.3.5.1. Market Revenue and Volume Forecast, by Type (2020-2032)
11.3.5.2. Market Revenue and Volume Forecast, by Indication (2020-2032)
11.3.5.3. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
11.3.6. Japan
11.3.6.1. Market Revenue and Volume Forecast, by Type (2020-2032)
11.3.6.2. Market Revenue and Volume Forecast, by Indication (2020-2032)
11.3.6.3. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Volume Forecast, by Type (2020-2032)
11.3.7.2. Market Revenue and Volume Forecast, by Indication (2020-2032)
11.3.7.3. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
11.4. MEA
11.4.1. Market Revenue and Volume Forecast, by Type (2020-2032)
11.4.2. Market Revenue and Volume Forecast, by Indication (2020-2032)
11.4.3. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
11.4.4. GCC
11.4.4.1. Market Revenue and Volume Forecast, by Type (2020-2032)
11.4.4.2. Market Revenue and Volume Forecast, by Indication (2020-2032)
11.4.4.3. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
11.4.5. North Africa
11.4.5.1. Market Revenue and Volume Forecast, by Type (2020-2032)
11.4.5.2. Market Revenue and Volume Forecast, by Indication (2020-2032)
11.4.5.3. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
11.4.6. South Africa
11.4.6.1. Market Revenue and Volume Forecast, by Type (2020-2032)
11.4.6.2. Market Revenue and Volume Forecast, by Indication (2020-2032)
11.4.6.3. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Volume Forecast, by Type (2020-2032)
11.4.7.2. Market Revenue and Volume Forecast, by Indication (2020-2032)
11.4.7.3. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
11.5. Latin America
11.5.1. Market Revenue and Volume Forecast, by Type (2020-2032)
11.5.2. Market Revenue and Volume Forecast, by Indication (2020-2032)
11.5.3. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
11.5.4. Brazil
11.5.4.1. Market Revenue and Volume Forecast, by Type (2020-2032)
11.5.4.2. Market Revenue and Volume Forecast, by Indication (2020-2032)
11.5.4.3. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Volume Forecast, by Type (2020-2032)
11.5.5.2. Market Revenue and Volume Forecast, by Indication (2020-2032)
11.5.5.3. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
Chapter 12. Company Profiles
12.1. Generex Biotechnology Corporation
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Advaxis Inc.
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Immunocellular Therapeutics, Ltd
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Vaccinogen, Inc.
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. GlaxoSmithKline plc (GSK)
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Merck & Co., Inc.
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Dynavax Technologies Corporation
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. SANPOWER GROUP CO. LTD. (DENDEREON CORPORATION)
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Amgen Inc.
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. UbiVac
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
14.2. Glossary of Terms
Contact Us:
Mr. Alex
Sales Manager
Call: +1 9197 992 333
Email: sales@precedenceresearch.com
Web: https://www.precedenceresearch.com
Blog: https://www.expresswebwire.com/
Blog: https://www.uswebwire.com/
